Fig. 1From: Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancerSurvival outcomes for patients with advanced EGFR-mutated (EGFR +) NSCLC. A Progression-free survival (PFS) in patients with and without ATB use. B Overall survival (OS) in patients with and without ATB use. C PFS in patients with and without POB use. D OS in patients with and without POB use. ATB antibiotic, POB probiotic.Back to article page